MRNA May 2024 95.000 put
| Previous close | 1.3800 |
| Open | 1.4500 |
| Bid | 0.0000 |
| Ask | 0.6100 |
| Strike | 95.00 |
| Expiry date | 2024-05-24 |
| Day's range | 0.2500 - 1.0100 |
| Contract range | N/A |
| Volume | |
| Open interest | 21 |
- Yahoo Finance Video
Moderna CEO on the changing COVID market: Pandemic to endemic
Shares of pharmaceutical company Moderna (MRNA) are on the rise despite first quarter losses. Moderna CEO Stéphane Bancel tells Yahoo Finance Senior Reporter Anjalee Khemlani that the company is busy developing updated coronavirus vaccines for the 2024-2025 season and recently announced an expansion into the Brazilian market. As the coronavirus pandemic has shifted toward an endemic, Bancel explains how Moderna continues to innovate, sharing a positive outlook on phase two data for a combination flu and coronavirus vaccine. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
GuruFocus.comModerna Inc (MRNA) Q1 2024 Earnings: Significant Revenue Decline Amid Strategic Shifts
Comparative Analysis of Q1 Financials Against Analyst Expectations
ZacksModerna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
Moderna (MRNA) delivered earnings and revenue surprises of 14.48% and 33.88%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
